Treatment of first recurrences of Clostridium difficile-associated disease: Waiting for new treatment options

Clinical Infectious Diseases

Volumn 42, Issue 6, 2006, Pages 765-767

  Louie, Thomas J ^a  

^a FOOTHILLS HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BACITRACIN; FUSIDIC ACID; METRONIDAZOLE; NEW DRUG; NITAZOXANIDE; POLYSTYRENE; RIFAXIMIN; TEICOPLANIN; TIACMICIN B; TOLEVAMER; UNCLASSIFIED DRUG; VANCOMYCIN;

BACTERIAL FLORA; BACTERIAL INFECTION; CLOSTRIDIUM DIFFICILE; EDITORIAL; EXPERIENCE; GROWTH INHIBITION; HOSPITALIZATION; HUMAN; NONHUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; RECURRENT DISEASE; RECURRENT INFECTION; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; DISEASE OUTBREAKS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; QUEBEC; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME;

EID: 33644843614     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/501137     Document Type: Editorial

References (19)

1. Pepin J, Routhier S, Gagnon S, Brazeau I. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis 2006; 42:758-64 this issue).
2. McDonald L, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353:2433-41.
3. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353:2442-9.
4. Pepin J, Alary M-E, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005; 40:1591-7.
5. Musher DM, Saima A, Logan N, et al. A relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005; 40:1586-90.
6. Gerding DN. Metronidazole for Clostridium difficile-associated disease: is it okay for mom? Clin Infect Dis 2005; 40:1598-600.
7. Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhea in six patients. Lancet 1989; 1:1156-60.
8. Pepin J, Valiquette L, Alary M-E, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004; 171:466-72.
9. Edlund C, Barkholt L, Olsson-Liljequist B, Nord CE. Effect of vancomycin on intestinal flora of patients who previously received antimicrobial therapy. Clin Infect Dis 1997; 25:729-32.
10. Wullt M, Odenholt I. A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea. J Antimicrob Chemother 2004; 54:211-6.
11. Wenisch C, Parschalk B, Hasenhundl M, Hirschl AM, Graninger W. Comparison of vancomycin, teichoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996; 22:813-8.
12. Dudley MN, McLaughlin JC, Carrington G, Frick J, Nightingale CH, Quintiliani R. Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea: a randomized double-blind trial. Arch Intern Med 1986; 146:1101-4.
13. de Lalla F, Nicolin R, Rinaldi E, et al. Prospective study of oral teichoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother 1992; 36:2192-6.
14. Davidson D, Peppe J, Louie T, et al. A phase 2 study of the toxin binding polymer tolevamer in patients with C. difficile associated diarrhea [abstract P548]. In: Program and abstracts of the 14th European Congress on Clinical Microbiology and Infectious Diseases (Prague). 2004.
15. Louie TJ, Emery J, Krulicki W, Byrne B, Mah M. PAR-101 is selectively effective against C. difficile in vivo and has minimal effect on the anaerobic fecal flora [poster LB2-30]. In: Proceedings of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). Washington, DC: American Society for Microbiology, 2005.
16. Testa R, Eftimiadi C, Sukkar GS, De Leo C, Rovida S, Shito GC, Celle G. A non-absorbable rifamycin for treatment of hepatic encephalopathy. Drugs Exp Clin Res 1985; 11:387-92.
17. Kokkotou E, Mustafa N, O'Brien M, Pothoulakis C, Kelly CP. Rifaximin: a novel non-absorbed antibiotic therapy for Clostridium difficile-associated diarrhea [poster B-35]. In: Proceedings of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). Washington, DC: American Society for Microbiology, 2005.
18. McVay CS, Rolfe RD. In vitro and in vivo activities of nitazoxanide against Clostridium difficile. Antimicrob Agents Chemother 2000; 44:2254-8.
19. Lewis S, Burmeister S, Brazier J. Effect of the prebiotic oligofructose on relapse of Clostridium difficile-associated diarrhea: a randomized, controlled study. Clin Gastroenterol Hepatol 2005; 3:442-8.